
XFOR Stock Forecast & Price Target
XFOR Analyst Ratings
Bulls say
X4 Pharmaceuticals Inc. demonstrates a positive financial outlook, projecting total revenues to reach $6.1 million in 2025 and escalating to $251 million by 2031, indicating significant long-term growth potential. The exclusive licensing agreement with Norgine Pharmaceuticals, covering Europe, Australia, and New Zealand, is expected to contribute escalating double-digit royalties, further enhancing revenue streams. Despite current market adoption challenges for mavorixafor, the international expansion and strategic management measures are viewed as prudent steps toward maximizing long-term profitability and geographic reach.
Bears say
X4 Pharmaceuticals's outlook is negatively impacted by several factors, including a strategic restructuring that entails a 30% reduction in workforce and an anticipated annual spending decrease of $30-$35 million. Furthermore, the company has revised its revenue projections for Xolremdi downward for 2025 due to changes in their commercial strategy, indicating potential challenges in generating expected revenue. Additionally, critical delays in market entry for its therapies, including WHIM syndrome and CN in both the US and EU, extend timelines significantly, contributing to concerns about the company's growth prospects and operational efficiency.
This aggregate rating is based on analysts' research of X4 Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.
XFOR Analyst Forecast & Price Prediction
Start investing in XFOR
Order type
Buy in
Order amount
Est. shares
0 shares